Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Original Article
S.J. Nicholls, I. Pavo, D.L. Bhatt, J.B. Buse, S.D. Prato, S.E. Kahn, A.M. Lincoff, D.K. McGuire, D. Miller, M.A. Nauck, H. Nishiyama, S.E. Nissen, N. Sattar, G. Weerakkody, R.J. Wiese, B. Zinman, S. Zoungas, J. Basile, M.J. Davies, F. Giorgino, M. Kellerer, L. Ji, T. Varkonyi, V. Menon, J.C. Broder, A. Herschtal, and D. D’Alessio
N Engl J Med 2025;393:2409-2420
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.

Facebook
X
LinkedIn
Forward